PLEASANTON, Calif., July 9 /PRNewswire-FirstCall/ -- Thoratec Corporation , a world leader in products to treat cardiovascular disease, said today that it will be participating in the C.E. Unterberg Towbin Emerging Growth Opportunities Conference on Wednesday, July 11.
David Smith, executive vice president and chief financial officer, will provide an update on the company, beginning at 1 p.m., Eastern Daylight Time (10 a.m., Pacific Daylight Time).
The presentation will be available through the conference website at http://www.wsw.com/webcast/ceut6/thor/, and on the company’s website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company’s product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 11,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s website at http://www.thoratec.com or http://www.itcmed.com.
Thoratec Corporation
CONTACT: David Smith, Executive Vice President, Chief Financial Officer ofThoratec Corporation, +1-925-847-8600; or Neal B. Rosen of Kalt RosenGroup-Ruder Finn West, +1-416-692-3058, for Thoratec Corporation
